Evidence map›Paper›PMID 39082787›Full record

ArticlemBio2024

Inhibition of host 5-lipoxygenase reduces overexuberant inflammatory responses and mortality associated with

Natalia Castro-Lopez, Althea Campuzano, Elysa Mdalel, Difernando Vanegas, Ashok Chaturvedi, Phung Nguyen, Mark Pulse, Astrid E Cardona, Floyd L Wormley

Abstract read
In one paragraph

Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Natalia Castro-LopezDepartment of Biology, Texas Christian University, Fort Worth, Texas, USA.
Althea CampuzanoDepartment of Molecular Microbiology and Immunology, The University of Texas at San Antonio, San Antonio, Texas, USA.ORCID 0000-0003-3159-7113
Elysa MdalelSouth Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, Texas, USA.
Difernando VanegasSouth Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, Texas, USA.
Ashok ChaturvediSouth Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, Texas, USA.
Phung NguyenDepartment of Pharmacology, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Mark PulseDepartment of Pharmacology, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Astrid E CardonaSouth Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, Texas, USA.
Floyd L WormleyDepartment of Biology, Texas Christian University, Fort Worth, Texas, USA.ORCID 0000-0001-9290-3925

Funding

UTSA RISE Research Training ProgramR25GM060655 · NIGMS · UNIVERSITY OF TEXAS SAN ANTONIO · PI BAREA-RODRIGUEZ, EDWIN J · 2000 to 2022
$21.6M
5-Lipoxygenase Inhibition as a Therapy to Prevent Cryptococcus-related IRISR21AI158260 · NIAID · TEXAS CHRISTIAN UNIVERSITY · PI WORMLEY, FLOYD L. · 2021 to 2022
$316k
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R21AI158260NIGMS NIH HHS R25 GM060655
6 · The paper itself

Abstract

Cryptococcosis, caused by fungi of the genus IMPORTANCE: Cryptococcosis is a mycosis with worldwide distribution and has a broad range of clinical manifestations, including diseases of the CNS. Globally, there is an estimated 179,000 cases of cryptococcal meningitis, resulting in approximately 112,000 fatalities per annum and 19% of AIDS-related deaths. Understanding how host immune responses are modulated during cryptococcosis is central to mitigating the morbidity and mortality associated with cryptococcosis. Leukotrienes (LTs) have been shown to modulate inflammatory responses during infection. In this study, we show that mice deficient in 5-lipoxygenase (5-LO), an enzyme central to the metabolism of arachidonic acid into leukotrienes, exhibit reduced pathology, disease, and neurological signs associated with cryptococcal meningitis. Additionally, mice given an experimental cryptococcal infection and subsequently treated with an FDA-approved 5-LO synthesis inhibitor exhibited significantly reduced mortality rates. These results suggest that therapeutics designed to inhibit host 5-LO activity could significantly reduce pathology and mortality rates associated with cryptococcal meningitis.

Indexed as

Arachidonate 5-LipoxygenaseCryptococcosisMeningoencephalitisMice, Inbred C57BLAnimalsCryptococcusDisease Models, AnimalFemaleHydroxyureaInflammationLipoxygenase InhibitorsMiceMice, KnockoutArachidonate 5-LipoxygenaseHydroxyureaLipoxygenase Inhibitorszileuton5-lipoxygenaseCryptococcosisCryptococcusCryptococcus deneoformansCryptococcus neoformansfungal immunologyhost–pathogen interactionsimmunitymedical mycologymeningitismeningoencephalitismicrobial pathogenesis

Identifiers

PMID39082787
PMCPMC11389364

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.